|Home | About | Journals | Submit | Contact Us | Français|
Our laboratory has had a longstanding interest in how the interactions between tumors and their microenvironment affect malignant progression. Recently, we have focused on defining the proteolytic pathways that function in the transition of breast cancer from the pre-invasive lesions of ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDCs). We use live-cell imaging to visualize, localize and quantify proteolysis as it occurs in real-time and thereby have established roles for lysosomal cysteine proteases both pericellularly and intracellularly in tumor proteolysis. To facilitate these studies, we have developed and optimized 3D organotypic co-culture models that recapitulate the in vivo interactions of mammary epithelial cells or tumor cells with stromal and inflammatory cells. Here we will discuss the background that led to our present studies as well as the techniques and models that we employ.
The initial working hypothesis for those studying proteases in cancer was that invasive processes (local and during metastatic spread) required degradation of extracellular matrices by proteases. The roles of proteases in cancer are now known to be much broader, including roles in premalignant lesions, growth, and angiogenesis. Furthermore, any one protease may function differently during the early and late stages of tumor progression (for recent comprehensive reviews on proteases in cancer, see ). The proteases themselves derive not only from tumor cells, but also from the multiple cell types present in the tumor stroma, e.g., fibroblasts, macrophages, mast cells, leukocytes, and endothelial cells. An impediment to determining how proteases function in tumors is that a purified protease capable of cleaving a potential substrate in vitro may not be the protease or the single protease responsible for degradation of that substrate in vivo. The in vivo functions of proteases are being studied through the use of transgenic mice deficient in specific proteases. Such studies have been informative; however, relying solely on this approach is problematic for several reasons including: 1) the large number of proteases (~560 in the human genome [2–4]), 2) the interplay between proteases and their endogenous inhibitors and activators, and 3) the redundancy among proteases and the observations of compensatory changes in other proteases. An example of the latter has been found to occur in a transgenic murine model for the development of mammary cancer in which there is altered cell surface expression of the lysosomal cysteine protease cathepsin X in mice deficient in another lysosomal cysteine protease, i.e., cathepsin B . Since proteases of more than one catalytic-type can cleave the same substrate, we would expect that compensatory changes could occur in which deficiency of one class of proteases results in alterations in expression of another class of proteases, e.g., a deficiency in a serine protease might result in alterations in a matrix metalloproteinase (MMP). Such complex interactions will be difficult to detect. Although the biological roles of proteases might be analyzed more successfully in genetically engineered murine cancer models in which the protease gene alleles are latent, conditional or inducible (for review, see [6, 7]), the number of proteases in the cancer degradome will likely restrict the use of such models to only a few proteases.
The complete repertoire of proteases known to be associated with human cancer, i.e., the cancer degradome (for review, see ), includes proteases of five catalytic types: aspartic, cysteine, metallo, serine and threonine. Examples of proteases that represent the five catalytic types are: cathepsin D (aspartic), caspases and cathepsin B (cysteine), MMP-9 and ADAM10 (metallo), plasmin and cathepsin G (serine), and the proteasome (threonine). Tumor invasion and metastasis are often assumed to be processes that involve only extracellular soluble proteases and membrane proteases, e.g., MMPs, membrane type-MMPs (MT-MMPs) such as MT1-MMP or MMP-14 and type II transmembrane serine proteases (TTSPs) such as matriptase (for recent reviews, see [8–10]). Indeed, there is extensive and compelling preclinical data implicating MMPs in malignant progression. Nonetheless, the clinical trials on MMP inhibitors (MMPIs) did not fulfill the promise of MMPs as therapeutic targets in cancer. There are several possible explanations for this apparent disconnect between the preclinical and clinical data (for reviews, see [11–14]) and there is still a widespread belief that tumor proteolysis is an extracellular process that involves primarily MMPs.
Intracellular proteases although less commonly implicated in tumor invasion and metastasis mediate invasion in lower organisms such as parasites. Invasion of plasmodium and toxoplasma, the parasites responsible for malaria and toxoplasmosis, respectively, occurs as a result of the secretion of vacuolar cysteine proteases and can be abolished with cysteine protease inhibitors (for reviews, see [15–17]). The working hypothesis in our laboratory has been that the mammalian counterparts of these enzymes, i.e., the lysosomal cysteine cathepsins, play comparable roles in the invasive processes associated with human cancers (for review, see ). As discussed below, some of these proteases are secreted from tumor cells and bind to the cell surface. Whether the primary role of cysteine cathepsins in cancer is pericellular, intracellular or both is not yet clear. We have shown that cysteine cathepsins participate in degradation of extracellular matrix proteins intracellularly and pericellularly. Contrary to our expectations, intracellular degradation by cysteine cathepsins occurred in the highly invasive BT549 breast carcinoma cells and pericellular degradation in the less invasive BT20 breast carcinoma cells . Others have confirmed an intracellular role for cysteine cathepsins in degradation of collagens, a role that is causally linked to invasive growth of mammary tumors , progression of prostate cancers  and migration and invasion of glioma cell lines . The collagens were taken up into the lysosomes via the endocytic collagen receptor uPARAP (urokinase plasminogen activator receptor associated protein)/Endo180. Activity of MT1-MMP, activation of MMP-2 by MT1-MMP and activity of uPA all have been shown to be regulated by uPARAP , thus indicating the critical functional interactions among pericellular and intracellular proteases that contribute to collagen degradation specifically and more generally to ‘tumor proteolysis’.
Sylven and colleagues reported an association of lysosomal proteases with cancer in 1957  and later specifically an association of the lysosomal cysteine protease cathepsin B with tumor cell surfaces . Subsequent studies reported secretion of lysosomal proteases: cathepsin B from human breast carcinoma explants [26, 27]; cathepsin L, another lysosomal cysteine protease, from transformed murine fibroblasts ; and cathepsin D, a lysosomal aspartic protease, from the human MCF7 breast carcinoma cell line . We have shown that an acidic tumor microenvironment increases secretion of cathepsin B  and identified p11 or the light chain of the annexin II heterotetramer as a binding partner that mediates association of cathepsin B with the tumor cell surface  and specifically with caveolar lipid rafts [32–34]. In Figure 1A, we illustrate these known interactions of cathepsin B and a number of other proteases (serine and metallo) with caveolae (for reviews, see [18, 35, 36]).
The failures of MMPIs in clinical trials resulted in allegations that MMPs, and by extrapolation other proteases, are not appropriate therapeutic targets in cancer. Is this the case or might the failure of the MMPI trials reflect problems in clinical trial design for cytostatic agents (see [12, 37, 38] for discussion of clinical trials)? Among the critical questions is whether the MMPIs actually reached and reduced the activity of their target MMPs in vivo. The MMPI trials did not include surrogate endpoints so it is not known whether MMPs were actually inhibited in the test patients [38–40]. Clinical trials without surrogate endpoints to monitor and confirm the efficacy of the therapeutic strategies being tested should not be viewed as definitive [39, 40]. There are other concerns about the MMPI trials. Coussens et al.  cite data revealing that the tumors studied in the clinical trials did not necessarily express the particular proteases targeted by the MMPIs. None of the clinical trials with BAY 12-9566 or other MMPIs included patients with breast cancers although this is a cancer for which there is strong preclinical evidence that MMPs impact progression. For example, Sledge and colleagues  have demonstrated efficacy for BAY 12-9566 in an orthotopic human breast model. Furthermore, not all MMPs should be inhibited; this is clearly true for MMP-8 (collagenase-2), an MMP expressed by inflammatory neutrophils, which plays a protective role in skin cancer . Similar observations have been made for cathepsin L, a cysteine protease with broad substrate specificity . Cathepsin L plays a protective role in both viral- and carcinogen-induced tumor progression in the mouse epidermis [44, 45]. In mice deficient in cathepsin L, the protection can be restored by transgenic expression of the human orthologue cathepsin V or L2 . Such data on cathepsins L/V, MMP-8 and other MMPs [46, 47] raise the possibility that broad-spectrum inhibitors such as the MMPIs used in clinical trials might have unanticipated side effects and indicate how essential it is to define the intended protease targets before using protease inhibitors for cancer therapy . Unanticipated side effects did occur in the clinical trials, limiting the amount of MMPIs that the patients could take and necessitating MMPI-free holidays in some patients . How endogenous protease inhibitors factor into the equation is also of relevance. Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been shown to promote carcinogenesis of squamous cell carcinoma of the skin, exerting “differential regulation on tissues in a stage-dependent manner” . TIMP-2 binds to MT1-MMP and in so doing acts as a receptor for proMMP-2, thereby activating MMP-2 on the cell surface . TIMPs also can affect tumor proliferation and apoptosis by metalloprotease-independent as well as metalloprotease-dependent mechanisms . In short, we are still far from having a thorough understanding of the roles of proteases in malignant progression: this includes understanding the roles of MMPs (see also ), the roles of other catalytic-types of proteases, how those roles may change during the course of malignant progression, whether the critical proteases come from tumor and/or tumor-associated cells, and whether the critical proteases are affected by interactions of the tumor with its microenvironment, etc. Despite ample preclinical evidence that proteases function in the progression of cancer, we do not yet know which protease(s) is the most appropriate target for an anti-protease therapy in a particular cancer or when during the course of cancer development and progression an anti-protease therapy might prove most effective. We might move substantially closer to answers to these questions if we consider the interplay between different proteases within networks; it is becoming quite clear that inhibition of a single protease or a single family of proteases is not sufficient to alter cancer progression.
Proteases interact with one another in networks that are generally comprised of more than one catalytic-type of protease (for reviews, see [53–56]). Intracellularly, the colocalization of proteases in structures such as lysosomes and proteasomes or in complexes such as inflammasomes facilitates these networks [57–59]. In a comparable fashion, interactions among proteases at the cell surface may be enhanced by the clustering of proteases within specialized structures, such as caveolar lipid rafts (Figure 1A [60, 61]) and invadopodia (Figure 1B; for review, see ). Yamaguchi et al. [9, 63] have linked caveolae to the formation of invadopodia and to degradation of extracellular matrix by breast cancer cells. The cartoons of Figure 1 depict potential interactions among proteases that have been localized to caveolae (Figure 1A) and to invadopodia (Figure 1B). The presence of proteolytic networks in these specialized membrane structures may speak to the critical roles played by protease interactions at the tumor cell surface rather than to the importance of any single protease on the tumor cell surface.
Caveolae are a subset of lipid microdomains within the plasma membrane that are identifiable as flask-shaped invaginations in electron micrographs. The structural protein responsible for the formation of caveolae is caveolin-1 as confirmed by an absence of caveolae in mice deficient in this protein . Increased expression of caveolin-1 has been correlated with a number of cancers: advanced prostate and breast , bladder , renal , lung , esophageal  and colon [70–72]. In head and neck cancer, caveolin-1 has been reported to function as an oncogene . Others contend that caveolin-1 is a tumor suppressor (for review, see ). These contradictory findings may reflect tumor type and stage and the constituents of the caveolae ([32, 33] and for review, see ) as well as the putative roles for caveolin-1 in lipid microdomains other than caveolae (for review, see ).
Caveolae are abundant in a wide variety of cells. This includes endothelial cells and adipocytes in which caveolin-1 has been shown to play distinct roles . Proteases of the cysteine, serine and metallo catalytic-types have been localized to caveolae, e.g., cathepsin B, plasmin[ogen], urokinase plasminogen activator (uPA), MMPs -2, -9 -11, -13, -14 (for review, see ), as have cell surface binding proteins for proteases. These include the annexin II heterotetramer that binds plasmin[ogen] [78, 79] and pro-cathepsin B , the urokinase plasminogen activator receptor (uPAR) that binds both inactive and active forms of uPA . Some of the proteases, their binding partners and how they interact are illustrated in Figure 1A. For example, active cathepsin B, shown in the cartoon as a teal structure labeled CTSB, can activate pro-uPA to its active form, which can activate plasminogen to plasmin. MMPs can also be activated in caveolae: pro-MMP-9 by plasmin and MMP-2 by MMP-14 in complex with its inhibitor TIMP-2. We hypothesize that this clustering of proteases leads to activation of proteolytic networks involving the cooperation of several families of proteases.
The colocalization of proteases in caveolae is associated with coordinated endothelial cell migration and formation of tube-like structures  and invasion and degradation of type IV collagen by tumor cells . Interfering with this colocalization results in reduced migration and proteolytic activity. For example, in annexin II-null endothelial cells, there is reduced activation of plasmin, MMP-9 and -13 as well as less directed cell migration and vessel sprouting . In colon cancer cells, down-regulation of caveolin-1 decreases the association of cathepsin B and its binding protein p11 and uPA and its receptor uPAR with caveolae fractions, coinciding with decreased degradation of type IV collagen and invasion . The proteases associated with caveolae have been shown to activate downstream proteases and signaling cascades [83, 84]. This clustering of proteases in caveolae is thus the basis for our hypothesis that caveolae enhance focal matrix degradation associated with normal and pathological processes.
Podosomes and invadopodia are other structural elements that cluster proteolytic activity at specific sites. Podosomes are found in cells of myeloid lineage such as dendritic cells, macrophages and osteoclasts  and have been proposed to mediate protease-dependent cell migration [86, 87]. Invadopodia are membrane protrusions found in tumor cells through which proteases are delivered to participate in focal degradation and invasion [88, 89] (Figure 1B). Among the proteases that accumulate within invadopodia are MT1-MMP and the serine protease seprase or fibroblast activation protein (FAP) [9, 90, 91]; (Figure 1B). Intriguingly, lipid rafts and caveolin-1 have been linked to formation of invadopodia and extracellular matrix degradation [63, 92]. The relationship between podosomes and invadopodia is not well defined. Yamada and colleagues  analyzed this relationship in macrophages, fibroblasts and tumor cells grown on a 2D fibronectin matrix. By live-cell imaging, they observed that tumor cell invadopodia are associated with rapid ruffling of the membrane and formation of invasive filamentous protrusions. This was not observed in either macrophage podosomes or focal adhesions in the fibroblasts. On the other hand, van Goethem et al. [86, 94] have shown that macrophages grown in a 3D gelled collagen I matrix exhibit a mesenchymal migration, similar to that of tumor cells, that is associated with dynamic protrusions and is dependent on proteolytic activity. In this study, an additional level of complexity was apparent as the composition, architecture and stiffness of the matrix were found to affect the type of migration observed as well as whether the migration was protease-dependent. In contrast to tumor cells, in which MT1-MMP has been suggested to be the primary mediator of invasion , van Goethem et al.  found that MMPIs did not block the protease-dependent 3D mesenchymal migration of macrophages. They propose that lysosomal cysteine proteases such as cathepsin B are responsible, citing a study by Tu et al.  in which cathepsin B and lysosomal exocytosis were linked to matrix degradation and invasion by transformed fibroblasts. Another podosome-related degradation process that involves exocytosis of a lysosomal cysteine protease, i.e., cathepsin K, is osteoclastic bone resorption . Mice deficient in cathepsin K exhibit impaired bone resorption, which ultimately results in osteopetrosis . In osteoclasts, cathepsin K is secreted into a resorptive pit formed by a sealing zone of podosome units due to the exocytosis of lysosomes . As a result, lysosomal proton pumps are inserted into the osteoclast membrane, which in turn leads to acidification of the resorptive pit. Consistent with this is that functional proton pumps are present in plasma membranes of invasive tumor cells [100, 101]. Thus, comparable processes may be responsible for the acidification of the resorptive pit between osteoclasts and bone and the microenvironment surrounding solid tumors.
Among the emerging hallmarks added by Weinberg and Hanahan to their original 6 hallmarks of cancer  is the reprogramming of energy metabolism . This is often designated as the Warburg effect, named after Otto Warburg who first reported that tumor cells exhibit increased glucose consumption and the ability to survive and progress in acidic environments . A majority of solid tumors have an acidic microenvironment  with the extracellular pH (pHe) in tumors ranging from 5.3–7.2 [106, 107]. Acidification can be attributed to a combination of factors including chaotic tumor vasculature, increased aerobic glycolysis, increased export of lactic acid in concert with diminished buffering capacity of tumor interstitial fluids  and increased secretion of protons [109, 110]. Whatever the mechanism for acidification the result is a pericellular environment that would favor the activity of proteases such as cysteine cathepsins that have pH optima that are slightly acidic. In addition, an acidic pHe induces a redistribution of lysosomes to the tumor cell surface and secretion of their content of lysosomal proteases via a microtubule dependent process (; Figure 2). Although not experimentally confirmed, the movement of lysosomes to the tumor cell surface should result in insertion of proton pumps into the plasma membrane as has been shown in osteoclasts.
An acidic pericellular pH has several diverse effects that might enhance cancer progression. One could be to help tumors to escape immunosurveillance by inhibiting the immune response [112, 113]. For an in-depth discussion of the effects of an acidic pH on the innate immune system, see review by Lardner . Another is to promote angiogenesis by triggering expression of VEGF and IL-8 by the cancer cells [115–118]. Xu et al. systematically characterized VEGF upregulation following exposure to acidic pH via mechanisms resulting in activation of Ras, Raf, and ERK1/2 MAPK pathways and subsequent down-stream binding of the transcription factor AP-1 to the VEGF promoter . Additional transcription factors responding to acidic pH include NFkB and HIF2α, which also increase angiogenesis [115, 117, 118]. Acidic pH also increases the rupture of tumor-released micro-vesicles that contain angiogenic factors and proteases . Cathepsin B secreted via such micro-vesicles has been suggested to induce activation of MMP-2 and -9 and potentiates endothelial cell invasion in an acidic environment . Human and mouse melanoma cells exposed to an acidic pH before tail vein injection showed a significant increase in experimental lung metastases [121, 122]. Surprisingly, the enhanced metastasis induced by acidic pH can be reduced by putting sodium bicarbonate in the drinking water  a non-toxic treatment.
Most of the research in our laboratory has focused on one lysosomal enzyme, the cysteine protease cathepsin B (for reviews, see [60, 124–126]) and a few other papain-family cysteine cathepsins. Analysis of only cysteine cathepsins, however, does not allow us to define the complete repertoire of proteases that contribute to tumor proteolysis. Therefore, we have established a live cell confocal assay to study proteolysis of extracellular matrix proteins that are encountered by invading tumor cells. This assay employs dye-quenched (DQ) derivatives of the extracellular matrix proteins collagens I and IV . This is in contrast to assays measuring degradation of synthetic substrates that are selective for a specific protease or one catalytic-type of protease. We have used the DQ-substrates to analyze proteolysis in vitro by tumor cell lysates and conditioned media  and in situ by live tumor cells alone ([19, 128, 129]; Figure 3, also see supplemental movies) or in co-culture with stromal and inflammatory cells . By evaluating the degradation of DQ-collagen IV in the presence and absence of protease inhibitors, we have demonstrated that proteolytic networks are responsible for degradation of collagen IV. For the breast cancer cell lines analyzed, the proteases are cathepsin B, proteases of the plasminogen cascade and MMPs . For the colon cancer cell lines analyzed, they are cathepsin B and MMPs . A caveat to these findings is that as with any model this assay has limitations. The DQ-collagen substrates are heavily labeled with FITC and thus are no longer native proteins. This renders the DQ-collagens more readily cleavable than is endogenous type IV collagen and thus the proteases identified as cleaving these substrates will need to be confirmed by alternative techniques (for further discussion of assay limitations, see ). By evaluating the degradation of DQ-collagen IV at neutral and slightly acidic pHe (7.4 vs. 6.8), we have shown that the acidic microenvironment of tumors may substantially enhance tumor proteolysis (Figure 3, also see supplemental movies). Our data indicate that meaningful analyses of tumor proteolysis require assessment of the roles played by multiple proteases, how those proteases interact in networks and knowledge of the properties of the microenvironment in which the proteases are functioning. This includes the non-cellular (e.g., pHe) microenvironment as well as the cellular microenvironment. The incorporation of additional cell types into our analyses will be discussed below.
Liotta and Kohn  suggested that cancer therapies should target the stroma or the tumor-stroma interface. The need to target stroma is certainly true when using protease inhibitors, as cells present in the tumor-associated stroma (e.g., fibroblasts, endothelial cells, inflammatory cells, myofibroblasts) are all important sources of proteases (for reviews, see [132–137]). Stromal cells can also impact tumor proteolysis through the expression of endogenous protease inhibitors. Myofibroblasts, for example, are suggested to be the primary source of plasminogen activator inhibitor-1 (PAI-1) in human breast carcinomas . Therefore, we need to study proteolysis in the context of tumor cells interacting with other cells in their microenvironment, interactions that our group has worked to model in vitro in organotypic co-cultures.
In early studies, we had used organotypic co-cultures to establish that stromal cells significantly impact tumor proteolysis . Degradation of DQ-collagen IV is increased as much as 17-fold in live 3D co-cultures of stromal cells (fibroblasts or fibroblasts + macrophages) with breast or colon tumor cells . Furthermore, we demonstrated that serine proteases of the plasminogen cascade degrade DQ-collagen IV in organotypic colon tumor co-cultures, yet not in monotypic colon tumor cultures . These observations could impact whether protease inhibitors are efficacious in vivo. Also relevant to including stromal cells in co-cultures are observations that fibroblasts isolated from invasive ductal breast carcinomas, but not normal breast, can recruit other stromal cells, in this case blood monocytes, into 3D spheroids . Analyzing stromal components is crucial as infiltration of macrophages in vivo potentiates malignant progression of the tumors in a transgenic mouse model for mammary carcinoma [140, 141]. This is also the case for branching morphogenesis of the mammary gland [141, 142], a developmental process already known to be associated with proteolysis . The literature on protease expression by stromal cells and our findings in organotypic co-cultures  strongly suggest that delineating the proteases and protease inhibitors that contribute to tumor proteolysis will necessitate evaluating the roles of stromal cells in vitro in organotypic co-cultures, i.e., in systems in which we can dissect out the contribution of individual cell types to tumor proteolysis.
The regulation of protease activity by their endogenous inhibitors and activators, the redundancy among proteases and the complexity of their biological roles suggest that we also should take advantage of cell-based 3D models to analyze the functions of proteases in a more physiological context. Schmeichel and Bissell  describe how such models have demonstrated “a role for the stroma as an important regulator of epithelial function and carcinoma progression.” They also predict that, if 3D models were used for high-throughput screening of drugs, they will “yield molecules that will sustain efficacy in clinical trials.” In order to develop a tractable 3D model in which to study breast cancer progression model in vitro, we extended an established model for analyzing morphogenesis and oncogenic transformation of MCF-10A cells in a 3D laminin-rich, reconstituted basement membrane (rBM) overlay culture system [145, 146] to include premalignant and malignant variants of the benign parental MCF-10A cells [147–152]. The MCF-10A cells have previously been characterized in 3D rBM overlay culture as a model for normal mammary epithelia that exhibits apicobasal polarity, cell-cell junctions, strict control of cell proliferation and apoptosis, and formation of functional glandular structures [145, 146, 153]. When isogenic variants of MCF-10A cells are grown in 3D rBM overlay culture, there is increasing derangement of normal acinar structures that parallels progression of the variants to a malignant phenotype. This in vitro MCF-10A variant series includes stages of atypical hyperplasia, dysplasia and carcinoma  comparable to those observed in vivo in xenografts [150, 151]. Thus, we have in hand an in vitro model in which the causal roles of proteases and proteolytic pathways in progression to invasive carcinomas can be analyzed.
There is an extensive literature [155–168] on the role of the tumor microenvironment in promoting breast tumor progression. There is also striking evidence from mouse transgenic models of mammary carcinoma that the tumor microenvironment, including normal cellular constituents of mammary tissue or cells that infiltrate as a consequence of angiogenic or inflammatory processes, contributes to progression of these tumors [e.g., see [5, 20, 169–173]. Although increases in expression of proteases have long been associated with tumors, many of those proteases originate from cells that infiltrate the tumors rather than the tumor cells [e.g., see [173, 174]. For example, we have shown that co-culturing macrophages with breast carcinoma cells increases degradation of DQ-collagen IV by ~3-fold, whereas fibroblasts increase degradation ~15-fold .
To evaluate temporal, dynamic and reciprocal interactions between the epithelial components of breast tumors and other cell types that infiltrate into tumors, we have established 3D co-culture models that we term MAME for mammary architecture and microenvironment engineering. These complex organotypic 3D culture models represent a new paradigm for in vitro analyses of pathobiological processes for breast cancer, yet possess sufficient flexibility to be applicable to a wide variety of other cancers. Our MAME models: 1) incorporate multiple cell types, 2) allow regulated introduction of soluble factors, 3) allow collection of conditioned media without disturbing cultures, and 4) enable monitoring in real-time of quantitative relevant information. In Figure 4, we illustrate in a schematic form two types of MAME co-cultures: tripartite and mixed. In the tripartite cultures, the first layer is type I collagen in which breast fibroblasts are embedded. The second and third layers are the 3D rBM overlay cultures containing tumor cells such as the MCF-10A variants described above. For the mixed cultures, the two cell types are mixed before plating in rBM overlay cultures. We have maintained MAME cultures up to 24 days and imaged live cultures at intervals over that period. To demonstrate that MAME tripartite and mixed cultures can be used to assess changes in proteolysis, we mix DQ-collagen I with the first layer of type I collagen in the tripartite cultures and DQ-collagen IV with the rBM layer in both tripartite and mixed cultures. In Figure 5 (also see supplemental movies), we show examples of MAME tripartite co-cultures for MCF10.CA1d cells and WS-12Ti human breast tumor-associated fibroblasts over three weeks of growth. The fibroblasts can be observed to infiltrate into the cultures over this time period. A dramatic increase in size of the tumor structure as well as increased invasiveness and proteolysis are observed over the time in culture. In other studies, we have shown that a small molecule MET inhibitor can reduce both invasiveness and proteolysis , as can antagonists to a number of chemokines and cytokines (Sameni and Sloane, unpublished data). The fact that we can demonstrate such effects in MAME co-cultures supports their potential utility as a preclinical screening platform that can be used to identify druggable targets as well as test therapies that target tumors in the context of their microenvironment. This includes assessing whether proteolytic networks in the tumor microenvironment are druggable targets.
“Tumor proteolysis” represents a composite of the activity of proteases of multiple catalytic types: metallo, serine, cysteine, aspartic and threonine. Both secreted proteases and intracellular proteases contribute to “tumor proteolysis.” This includes lysosomal proteases, especially cysteine cathepsins, which act both intracellularly within the lysosome and pericellularly in association with specialized regions on the cell surface such as caveolae and invadopodia. These specialized regions cluster proteases in networks that enhance degradation of the extracellular matrix and invasiveness. “Tumor proteolysis” is affected by interactions of tumor cells with the cellular (fibroblasts, macrophages) and non-cellular (acidic pHe) components of the tumor microenvironment. We have taken advantage of live-cell imaging technology to characterize and localize the proteolytic activity of tumor cells and tumor-associated cells within a supportive 3D scaffold that recapitulates the architecture of developing tumors in vivo. This technology has allowed us to analyze and quantify the contributions of various cell types and the non-cellular microenvironment to the composite tumor proteolysis and to establish a role for lysosomal cysteine cathepsins in tumor proteolysis.
Animation of 3D reconstruction of confocal images depicted in Figure 3.
This work was supported by U.S. Public Health Service Grants: R01 CA56586, R01 CA131990, R01 CA131990S and U54 RR022241. The Microscopy, Imaging and Cytometry Resources core is supported by National Institutes of Health Center Grant P30 CA22453.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.